Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

TIGIT immune checkpoint blockade restores CD8+ T cell immunity against multiple myeloma.

Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ.

Blood. 2018 Jul 9. pii: blood-2018-01-825265. doi: 10.1182/blood-2018-01-825265. [Epub ahead of print]

PMID:
29986909
2.

Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23.

Yan J, Allen S, Vijayan D, Li XY, Harjunpää H, Takeda K, Liu J, Cua DJ, Smyth MJ, Teng MWL.

Cancer Immunol Res. 2018 Jun 19. doi: 10.1158/2326-6066.CIR-18-0011. [Epub ahead of print]

PMID:
29921599
3.

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL.

Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018.

PMID:
29900061
4.

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Ahern E, Harjunpää H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ.

Oncoimmunology. 2018 Feb 14;7(6):e1431088. doi: 10.1080/2162402X.2018.1431088. eCollection 2018.

PMID:
29872559
5.

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ.

J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14.

6.

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K, Takeda K, Bernhardt G, Teng MWL, Dougall WC, Smyth MJ.

Oncoimmunology. 2018 Feb 1;7(5):e1424677. doi: 10.1080/2162402X.2018.1424677. eCollection 2018.

PMID:
29721390
7.

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Gartlan KH, Varelias A, Koyama M, Robb RJ, Markey KA, Chang K, Wilkinson AN, Smith D, Ullah MA, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Teal BE, Cheong M, Teng MWL, Smyth MJ, Tey SK, MacDonald KPA, Hill GR.

Blood Adv. 2017 Jan 26;1(6):341-351. doi: 10.1182/bloodadvances.2016002980. eCollection 2017 Feb 14.

8.

De-novo and acquired resistance to immune checkpoint targeting.

Syn NL, Teng MWL, Mok TSK, Soo RA.

Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. Review.

PMID:
29208439
9.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Nov 22;17(12):765. doi: 10.1038/nrc.2017.110. No abstract available.

PMID:
29162946
10.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Dec;17(12):709-724. doi: 10.1038/nrc.2017.86. Epub 2017 Oct 23. Review. Erratum in: Nat Rev Cancer. 2017 Nov 22;17 (12 ):765.

PMID:
29059149
11.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

PMID:
29045907
12.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
13.

Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Yan J, Smyth MJ, Teng MWL.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028530. doi: 10.1101/cshperspect.a028530. Review.

PMID:
28716888
14.

PD1 functions by inhibiting CD28-mediated co-stimulation.

O'Donnell JS, Smyth MJ, Teng MWL.

Clin Transl Immunology. 2017 May 5;6(5):e138. doi: 10.1038/cti.2017.15. eCollection 2017 May. No abstract available.

15.

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Vijayan D, Barkauskas DS, Stannard K, Sult E, Buonpane R, Takeda K, Teng MWL, Sachsenmeier K, Hay C, Smyth MJ.

Oncoimmunology. 2017 Apr 5;6(5):e1312044. doi: 10.1080/2162402X.2017.1312044. eCollection 2017.

16.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ.

Clin Cancer Res. 2017 Oct 1;23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20.

PMID:
28634284
17.

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

O'Donnell JS, Massi D, Teng MWL, Mandala M.

Semin Cancer Biol. 2018 Feb;48:91-103. doi: 10.1016/j.semcancer.2017.04.015. Epub 2017 May 2. Review.

PMID:
28467889
18.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

19.

Resistance to PD1/PDL1 checkpoint inhibition.

O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. Review.

PMID:
27951441
20.

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

Cancer Res. 2016 Nov 1;76(21):6266-6277. Epub 2016 Sep 9.

21.

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ.

Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. Epub 2016 Sep 12. Review.

22.

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

O'Donnell JS, Smyth MJ, Teng MW.

Genome Med. 2016 Oct 25;8(1):111.

23.

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ, Teng MW.

Cancer Discov. 2016 Dec;6(12):1382-1399. Epub 2016 Sep 23.

24.

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ.

Cancer Cell. 2016 Sep 12;30(3):391-403. doi: 10.1016/j.ccell.2016.06.025.

25.

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW.

Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8.

26.

Checkpoint Immunotherapy: Picking a Winner.

Teng MW, Khanna R, Smyth MJ.

Cancer Discov. 2016 Aug;6(8):818-20. doi: 10.1158/2159-8290.CD-16-0694.

27.

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.

Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Kühnel F, Gurlevik E, Bernhardt G, Teng MW, Smyth MJ.

Cancer Discov. 2016 Apr;6(4):446-59. doi: 10.1158/2159-8290.CD-15-0944. Epub 2016 Jan 19.

28.

Combination cancer immunotherapies tailored to the tumour microenvironment.

Smyth MJ, Ngiow SF, Ribas A, Teng MW.

Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. doi: 10.1038/nrclinonc.2015.209. Epub 2015 Nov 24. Review.

PMID:
26598942
29.

TIGIT predominantly regulates the immune response via regulatory T cells.

Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC.

J Clin Invest. 2015 Nov 2;125(11):4053-62. doi: 10.1172/JCI81187. Epub 2015 Sep 28.

30.

From mice to humans: developments in cancer immunoediting.

Teng MW, Galon J, Fridman WH, Smyth MJ.

J Clin Invest. 2015 Sep;125(9):3338-46. doi: 10.1172/JCI80004. Epub 2015 Aug 4. Review.

31.

Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects.

Gartlan KH, Markey KA, Varelias A, Bunting MD, Koyama M, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Cheong M, Teal BE, Lor M, Comerford I, Teng MW, Smyth MJ, McCluskey J, Rossjohn J, Stockinger B, Boyle GM, Lane SW, Clouston AD, McColl SR, MacDonald KP, Hill GR.

Blood. 2015 Sep 24;126(13):1609-20. doi: 10.1182/blood-2015-01-622662. Epub 2015 Jul 23.

32.

Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease.

Koyama M, Cheong M, Markey KA, Gartlan KH, Kuns RD, Locke KR, Lineburg KE, Teal BE, Leveque-El Mouttie L, Bunting MD, Vuckovic S, Zhang P, Teng MW, Varelias A, Tey SK, Wockner LF, Engwerda CR, Smyth MJ, Belz GT, McColl SR, MacDonald KP, Hill GR.

J Exp Med. 2015 Jul 27;212(8):1303-21. doi: 10.1084/jem.20150329. Epub 2015 Jul 13.

33.

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ.

Nat Med. 2015 Jul;21(7):719-29. doi: 10.1038/nm.3895. Epub 2015 Jun 29. Review.

PMID:
26121196
34.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 Jul 1;125(7):2904. doi: 10.1172/JCI82646. Epub 2015 Jun 15. No abstract available.

35.

Classifying Cancers Based on T-cell Infiltration and PD-L1.

Teng MW, Ngiow SF, Ribas A, Smyth MJ.

Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255. Review.

36.

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Devaud C, Westwood JA, Teng MW, John LB, Yong CS, Duong CP, Smyth MJ, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Dec 21;3(11):e963395. eCollection 2014 Nov.

37.

Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.

Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ.

Oncoimmunology. 2014 Dec 15;3(10):e958952. eCollection 2014 Nov.

38.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 May;125(5):2077-89. doi: 10.1172/JCI77181. Epub 2015 Apr 20. Erratum in: J Clin Invest. 2015 Jul 1;125(7):2904. Chesi, Martha [corrected to Chesi, Marta].

39.

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L.

Cell Res. 2015 Mar;25(3):399-400. doi: 10.1038/cr.2015.28. No abstract available.

40.

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L.

Cell Res. 2015 Feb;25(2):208-24. doi: 10.1038/cr.2015.3. Epub 2015 Jan 13. Erratum in: Cell Res. 2015 Mar;25(3):399-400. Zörnig, Inka [added]; Hassel, Jessica [added].

41.

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies.

Liu J, Blake SJ, Smyth MJ, Teng MW.

Clin Transl Immunology. 2014 Aug 1;3(8):e22. doi: 10.1038/cti.2014.18. eCollection 2014 Aug. Review.

42.

Role of IL-17 and IL-22 in autoimmunity and cancer.

Blake SJ, Teng MW.

Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:41-50. doi: 10.1016/S0001-7310(14)70017-1. Review.

PMID:
25398491
43.

Translational biology of osteosarcoma.

Kansara M, Teng MW, Smyth MJ, Thomas DM.

Nat Rev Cancer. 2014 Nov;14(11):722-35. doi: 10.1038/nrc3838. Epub 2014 Oct 16. Review.

PMID:
25319867
44.

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression.

Smyth MJ, Teng MW.

Oncoimmunology. 2014 May 23;3:e28964. eCollection 2014.

45.

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ.

Cancer Res. 2014 Jul 15;74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0957. Epub 2014 Jul 1.

46.

Targeting regulatory T cells in tumor immunotherapy.

Smyth MJ, Ngiow SF, Teng MW.

Immunol Cell Biol. 2014 Jul;92(6):473-4. doi: 10.1038/icb.2014.33. Epub 2014 Apr 29. No abstract available.

PMID:
24777313
47.

Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.

von Scheidt B, Leung PS, Yong MC, Zhang Y, Towne JE, Smyth MJ, Teng MW.

Cancer Res. 2014 May 1;74(9):2412-21. doi: 10.1158/0008-5472.CAN-13-1646. Epub 2014 Feb 20.

48.

Cancer. Can cancer trigger autoimmunity?

Teng MW, Smyth MJ.

Science. 2014 Jan 10;343(6167):147-8. doi: 10.1126/science.1249486. No abstract available.

PMID:
24408426
49.

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Cancer Res. 2014 Jan 15;74(2):436-45. doi: 10.1158/0008-5472.CAN-13-1265. Epub 2013 Dec 3.

50.

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH.

Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19.

Supplemental Content

Support Center